Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  219.93
+2.79 (1.28%)
AAPL  270.80
+4.55 (1.71%)
AMD  204.09
-1.93 (-0.94%)
BAC  51.61
+0.61 (1.20%)
GOOG  297.19
+7.21 (2.49%)
META  593.52
+4.37 (0.74%)
MSFT  474.88
-3.56 (-0.74%)
NVDA  181.28
+0.65 (0.36%)
ORCL  200.44
-10.25 (-4.86%)
TSLA  401.05
+5.82 (1.47%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.